JEITO

Did you know that pharmaceuticals represent a significant part of the trade between France and Denmark? 🇫🇷🇩🇰 Both countries are home to global leaders and rising biopharma companies with the potential to become tomorrow's champions. 🚀   JEITO is strongly involved in this cooperation, and was honored and grateful to Their Majesties King Frederik X and Queen Mary for being invited to take part in the France–Denmark Business Forum.   ➡️ NMD Pharma A/S, one of our portfolio companies and part of the Danish delegation, is a wonderful example of what this kind of cross-border collaboration can make possible. The biotech led by Thomas Holm Pedersen is developing life-changing therapies for people living with neuromuscular diseases. We've proudly supported them since 2022, alongside two leading Danish co-investors: Novo Holdings and Lundbeckfonden / Lundbeck Foundation. ➡️ This fruitful collaboration is also reflected in our ongoing exchanges with partners such as the BioInnovation Institute to support world-class life science innovation, in continuity to Rafaèle Tordjman's mission as France's Special Envoy for Health Innovation.   We are grateful for the opportunity to further deepen collaboration between our two countries in research and innovation, and to support the growth of the European life sciences ecosystem. #Innovation #Research #PrivateEquity #LifeSciences #Biopharma

Highly promising new data showing increased innervation of skeletal muscle from our portfolio company NMD Pharma A/S is driving research forward in neuromuscular diseases.   New data show the potential disease-modifying mechanism of ClC-1 inhibition in neuromuscular disorders. As a reminder, NMD Pharma develops novel, orally bioavailable, skeletal muscle-specific chloride ion channel (ClC-1) inhibitors.   Introduced at the Muscular Dystrophy Association Clinical & Scientific Conference in Dallas, Texas, the study suggests a potential disease-modifying mechanism of ClC-1 inhibition — possibly involving enhanced reinnervation or reduced denervation processes.   Congratulations for this major achievement with very strong potential for patients 👏   Learn more 👉 https://lnkd.in/eJ8T_Jn6   #Research #RareDisease #NeuromuscularDisease #MyastheniaGravia #Biopharma #Innovation

We are delighted to announce that we have co-led, alongside Novo Holdings, an oversubscribed €78 million financing round in Augustine Therapeutics, a biotech company focused on developing new therapies for neuromuscular, cardio-metabolic diseases, and neurodegenerative. Founded in 2019 in Belgium as a spin-off from the European excellence center VIB-KU Leuven, Augustine has identified a highly promising therapeutic approach for neurologic diseases, with a particular focus on Charcot-Marie-Tooth (CMT) disease, where therapeutic options remain extremely limited for patients. The funds will support the advancement of Augustine's lead candidate, AGT-100216, into the clinic with a Phase 1 will starting imminently. This financial round will support the clinical development including a Phase 2 proof-of-concept clinical trial in CMT, as well as the development of two additional programs in cardio-metabolic and neurodegenerative indications. With this investment and its expertise, JEITO reaffirms its commitment to tackling these severe diseases, an area where innovation holds great promise and the potential to change patients' lives. Read more 👉 https://lnkd.in/eim8d7_d #FasterForThePatient #privateequity #investment #lifesciences #biotech #CMT

JEITO, 1st biopharma fund in the Top 3 of European Growth Funds! 🏆 We are delighted to share that JEITO has been recognized by Private Equity Magazine as the 3rd growth fund in Europe for its investments in European companies in 2024. France and Europe are home to world-class scientific research. We are incredibly proud to support the entire life sciences ecosystem, helping biopharmaceutical companies transform breakthrough science into innovative treatments for patients with high unmet needs. In 2025, we are committed to pursuing our mission: go faster for the patients, further with the entrepreneurs. #FasterForThePatient #privateequity #growth #biopharma #innovation #healthcare

We are thrilled to announce that our founder and CEO Rafaèle Tordjman has been named 'Investor Woman of the Year' by the French leading Tech media Maddyness! 🏆 This distinction celebrates Rafaèle Tordjman's leadership and the dedication of the JEITO team in investing in innovation and driving value for patients and society. #MaddyInvestAwards #privatequity #finance #innovation #biopharma

The word "𝐉𝐞𝐢𝐭𝐨" in Brazilian Portuguese means "new way," as we truly believe that "Where there is a will, there is a way." As we celebrate International Women's Day today, this motto takes on its full meaning.   At JEITO, we are convinced that diversity and inclusion are drivers of sustainable growth in both business and society. That is why, once again this year, we are proud to demonstrate that this commitment is a 𝗿𝗲𝗮𝗹𝗶𝘁𝘆 𝗮𝘁 𝗝𝗲𝗶𝘁𝗼 (Jeito Sustainability Report 2024): 🔹 60% of our team is made up of women 🔹 50% of our investment team is female 🔹 Our four Partners, including Rafaèle Tordjman, our Founder and CEO, are women leaders And even more importantly, Jeito's collective team includes 11 nationalities. 𝗪𝗶𝘁𝗵𝗶𝗻 𝗼𝘂𝗿 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼: 🔹Women represent 61% of the teams 🔹Women hold 28% of Board positions, up from 18% in 2022 𝗕𝗲𝘆𝗼𝗻𝗱 𝗝𝗲𝗶𝘁𝗼: 🔹This commitment is a deep conviction carried by Dr. Rafaèle Tordjman, who founded Women Innovating Together in Healthcare 15 years ago. Today, this initiative proudly brings together more than 500 women from around the world, representing the entire medical innovation ecosystem. The power of gender, national, and visionary diversity is undeniably a driving force for better innovation in society. #IWD2025 #diversity #inclusion #womenleadership #privateequity #biopharma

At the East-West Biopharma Summit 2025, our Partner Ksenija Pavletic had the opportunity to share JEITO's vision on the growing innovation potential in Asia, as well as discussing the NewCo model in the biotech industry.   Our significant participation in the $187 million Series A financing of Callio Therapeutics—a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy—is a great illustration of its relevance and potential.   Thank you, Jeff Cranmer, BioCentury Inc., for the fruitful discussion with Ansbert Gadicke, M.D. (MPM BioImpact), Amit Kakar MD (Novo Holdings), Carl Firth (Panacea Venture), and Takaaki (Aki) Tobaru (Remiges Ventures, Inc.).   #BioCenturyEastWest #PrivateEquity #Biotech #LifeSciences #Innovation

We are thrilled to announce our significant participation in the $187 million financing round in Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. Four things to know about this investment, the company, and its technology: 1️⃣ Callio Therapeutics is developing the new generation of multi-payload ADC based on technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience.   2️⃣ The company is at the forefront of solving one of oncology’s biggest challenges: drug resistance with standard (or single payload) Antibody-Drug Conjugate (ADC) therapies   3️⃣ Led by CEO Piers Ingram, PhD, the company is backed by a founding management team with deep expertise in ADC development, bringing experience from top biotech and biopharma companies.   4️⃣ With the support of a premier investor syndicate, Callio Therapeutics will advance its HER2-targeted dual-payload ADC and a second undisclosed ADC program toward clinical proof-of-concept, all designed to maximize therapeutic benefit for cancer patients by overcoming the limitations of single-payload therapies   Through this investment, we proud to reinforce our commitment to supporting transformative oncology innovations for patients with high unmet need. Read more 👉 https://lnkd.in/gAcuucYB #privateequity #biotech #biopharma #lifesciences #oncology

300 million people worldwide live with one of the 6,000 existing rare diseases. Too many of them still have no treatment options, making the need for breakthrough therapies more urgent than ever. Supporting the most innovative biopharmaceutical companies developing breakthrough treatments is exactly what a fund like JEITO is here for. And this is well illustrated by some of our portfolio companies which are taking part in this fight against rare diseases, such as SparingVision, NMD Pharma A/S, Alentis Therapeutics or Pulmocide. We are proud to stand by your side for patients suffering from rare diseases. Thank you for your dedication! 👏 #RareDiseaseDay #Innovation #Biopharma #LifeSciences #RareDisease

🥁 Jeito’s white paper is out! Dive with us into the thriving biopharma landscape 👇   Over the past decade, global biopharma assets under management have grown fivefold. In “𝘛𝘩𝘦 𝘙𝘪𝘴𝘦 𝘰𝘧 𝘗𝘳𝘪𝘷𝘢𝘵𝘦 𝘐𝘯𝘷𝘦𝘴𝘵𝘮𝘦𝘯𝘵 𝘪𝘯 𝘉𝘪𝘰𝘱𝘩𝘢𝘳𝘮𝘢”, we analyze the key drivers behind this acceleration and the trends set to shape the industry's future.   🔬 The report explores key topics such as the outsourcing of R&D investments, the patent cliff, the impact of exclusivity loss in biopharma, the transformative role of AI, as well as long-term healthcare trends.    We are grateful to our esteemed contributors, including Paul Hudson (CEO of Sanofi), Christophe Weber (President and CEO of Takeda), Dr. Aradhana Sarin (Group CFO of AstraZeneca), and Pascal Touchon (Chairman of the Board Atara Biotherapeutics, for sharing their invaluable insights on the future of biopharma.   This white paper reinforces Jeito’s core belief: the value we create for patients ultimately defines the value we bring to all stakeholders and society.   📄 Download the full report here 👉 https://lnkd.in/eNz-AJAK   #FasterForThePatient #privateequity #innovation #lifescience #biopharma